New cancer drug YL211 enters first human tests

NCT ID NCT06384352

Recruiting now Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are to check safety and see if tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: YL211 (an antibody-drug conjugate given intravenously)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and it will take years before any potential treatment is confirmed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer gastric adenocarcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma hepatocellular carcinoma intrahepatic bile duct cancer neoplasm non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, Beijing Municipality, 100029, China
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
RECRUITING

Las Vegas, Nevada, 89169, United States
Florida Cancer Specialists & Research Institute (FCS) - Sarasota Cattlemen Office
RECRUITING

Sarasota, Florida, 34232-6422, United States
Gosford Hospital
RECRUITING

Gosford, New South Wales, 2250, Australia
Monash Health
RECRUITING

Melbourne, Australia
NEXT Oncology - Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology - Houston
RECRUITING

Houston, Texas, 77055, United States
NEXT San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
One Clinical Research - Nedlands
RECRUITING

Nedlands, Western Australia, 6009, Australia
Princess Margaret Hospital
RECRUITING

Toronto, Toronto, Canada
Sarah Cannon Research Institute (SCRI) at HealthONE
RECRUITING

Denver, Colorado, 80218-1238, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China
The First Affiliated Hospital - Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310003, China
The Ottawa Hospital - General Campus
RECRUITING

Ottawa, Canada
The University of Texas - MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Cincinnati Vontz Center for Molecular Studies
RECRUITING

Cincinnati, Ohio, 45219, United States
University of Colorado Hospital - Anschutz Cancer Pavilion
RECRUITING

Aurora, Colorado, 80045, United States
Wenzhou Medical University - The First Affiliated Hospital
RECRUITING

Wenzhou, Zhejiang, 325000, China
West China Hospital, Sichuan University
RECRUITING

Chengdu, China
Yale School of Medicine - Yale Cancer Center - Smilow Cancer Hospital Care Centers - North Haven
RECRUITING

North Haven, Connecticut, 06473-2142, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.